author-photo

Jacqulyne Ponville Robichaux

University of Texas MD Anderson Cancer Center

16

Papers

466

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non–small-cell Lung Cancer (NSCLC)

2019 Clinical Lung Cancer
Show All
- Source
- Cite
- Save
Citations (26)
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC

2018 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (156)
Abstract 4772: Poziotinib overcomes de novo resistance of HER2 exon 20 mutations in NSCLC and other cancers: Preclinical studies and initial clinical testing

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
COMPOSÉS À ACTIVITÉ ANTITUMORALE CONTRE DES CELLULES CANCÉREUSES PORTEUSES DE MUTATIONS EGFR OU HER2 EXON 20

2018
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 2956: Mechanisms of resistance for osimertinib for patients with EGFR-mutant lung cancer: MD Anderson Cancer Center single institution experience with osimertinib resistance

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

2018 Nature Medicine
Show All
- Source
- Cite
- Save
Citations (184)
Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (22)
OA 12.01 The Preclinical and Clinical Activity of Poziotinib, a Potent, Selective Inhibitor of EGFR Exon 20 Mutant NSCLC

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Abstract 2061: Non-covalent EGFR T790M targeting TKIs inhibit AZD9291 resistant EGFR C797S mutants

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
OA 09.05 Identification of Novel Potentially Targetable Genomic Alterations in Paired Tumors with Acquired EGFR TKI Resistance by NGS

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)